Aceruloplasminemia
Introduction
Aceruloplasminemia is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Aceruloplasminemia is a rare autosomal recessive neurodegenerative disorder characterized by the complete absence or severe deficiency of ceruloplasmin in the blood. Ceruloplasmin
is a copper-transporting enzyme encoded by the CP gene, and its deficiency leads to systemic iron overload, particularly affecting the brain, liver, and retina.[@harris1995]
Overview
Genetic Basis
Aceruloplasminemia is caused by homozygous or compound heterozygous mutations in the CP gene (chromosome 3q24), which encodes ceruloplasmin—a 1046-amino acid glycoprotein
synthesized primarily in the liver. Ceruloplasmin is the main copper transporter in plasma and plays a critical role in iron metabolism through its ferroxidase activity.[@hellman2000]
The disorder follows an autosomal recessive inheritance pattern. Over 40 pathogenic variants have been identified, including nonsense mutations, deletions, and splice-site
mutations that result in a complete loss or severe reduction of functional ceruloplasmin.[@kono2014]
Pathophysiology
Ceruloplasmin possesses ferroxidase activity that converts toxic Fe[@hellman2000]⁺ (ferrous iron) to Fe[@kono2014]⁺
(ferric
iron), which can then be bound by transferrin for safe transport. In aceruloplasminemia, this conversion is impaired, leading to:
...Aceruloplasminemia
Introduction
Aceruloplasminemia is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Aceruloplasminemia is a rare autosomal recessive neurodegenerative disorder characterized by the complete absence or severe deficiency of ceruloplasmin in the blood. Ceruloplasmin
is a copper-transporting enzyme encoded by the CP gene, and its deficiency leads to systemic iron overload, particularly affecting the brain, liver, and retina.[@harris1995]
Overview
Genetic Basis
Aceruloplasminemia is caused by homozygous or compound heterozygous mutations in the CP gene (chromosome 3q24), which encodes ceruloplasmin—a 1046-amino acid glycoprotein
synthesized primarily in the liver. Ceruloplasmin is the main copper transporter in plasma and plays a critical role in iron metabolism through its ferroxidase activity.[@hellman2000]
The disorder follows an autosomal recessive inheritance pattern. Over 40 pathogenic variants have been identified, including nonsense mutations, deletions, and splice-site
mutations that result in a complete loss or severe reduction of functional ceruloplasmin.[@kono2014]
Pathophysiology
Ceruloplasmin possesses ferroxidase activity that converts toxic Fe[@hellman2000]⁺ (ferrous iron) to Fe[@kono2014]⁺
(ferric
iron), which can then be bound by transferrin for safe transport. In aceruloplasminemia, this conversion is impaired, leading to:
- Reduced iron export: Iron cannot be efficiently exported from cells, causing intracellular iron accumulation
- Increased free radicals: Fe[@hellman2000]⁺ generates hydroxyl radicals through Fenton chemistry, causing oxidative damage
- Tissue iron overload: Iron accumulates in the brain (particularly the basal ganglia, thalamus, and cerebellum), liver, pancreas, and retina[@miyajima1999]
Neurodegeneration
The iron accumulation in the brain leads to:
- Neuronal loss in the basal ganglia and cerebellum
- Demyelination and axonal degeneration
- Astrogliosis (reactive astrocytosis)
- Microglial activation and neuroinflammation
The disease exemplifies the critical role of ferroxidase activity in neuronal survival, and serves as a model for understanding iron-induced neurodegeneration.[@ress2019]
Clinical Features
Neurological Symptoms
Neurological manifestations typically present in adulthood (third to fourth decade), though some patients show earlier onset:
- Movement disorders: Tremor, ataxia, chorea, dystonia, and parkinsonism
- Cognitive decline: Progressive dementia resembling Alzheimer's or Huntington's Disease
- Psychiatric symptoms: Depression, anxiety, personality changes
- Seizures: Focal or generalized seizures may occur
- Visual disturbances: Retinal degeneration and macular atrophy leading to progressive vision loss[@miyajima2015]
Systemic manifestations
- Anemia: Microcytic, hypochromic anemia despite iron overload (paradoxical iron sequestration)
- Hepatomegaly: Liver enlargement due to hepatic iron accumulation
- Diabetes mellitus: Iron-induced pancreatic β-cell dysfunction
- Retinal degeneration: Progressive retinopathy with bone spicule pigmentation
Laboratory Findings
- Absent or markedly reduced ceruloplasmin (<5 mg/dL; normal: 20-60 mg/dL)
- Low serum copper (<10 μg/dL; normal: 70-140 μg/dL)
- Elevated serum ferritin (>1000 ng/mL)
- Transferrin saturation near 100%
- Absent serum ferroxidase activity
Neuroimaging
MRI reveals characteristic T2 hypointensity in the:
- Globus pallidus
- Putamen
- [Thalamus](/brain-regions/thalamus)
- Cerebellar dentate nuclei
- Retina (on MR retina imaging)
These findings reflect iron deposition and help differentiate aceruloplasminemia from other forms of neurodegeneration with brain iron accumulation (NBIA).[@honda2010]
Diagnosis
Diagnostic Criteria
Clinical suspicion: Adult-onset movement disorder with cognitive decline and anemia
Laboratory confirmation:
- Ceruloplasmin <5 mg/dL
- Serum copper <10 μg/dL
- Ferritin >1000 ng/mL
3.
Genetic testing: Biallelic pathogenic variants in CP gene
Neuroimaging: MRI showing iron deposition in basal ganglia and cerebellumDifferential Diagnosis
- Other NBIA disorders (PKAN, PLAN, FA2H, WDR45)
- Hemochromatosis
- Wilson's Disease
- Friedreich's Ataxia
Treatment
Iron Chelation Therapy
Iron chelation is the primary treatment approach:
- Deferoxamine: Subcutaneous infusion; may reduce brain iron levels but limited CNS penetration
- Deferasirox: Oral chelator; better CNS penetration; shown to reduce MRI signal abnormalities
- Combination therapy: Deferasirox with occasional deferoxamine may provide optimal iron removal
Experimental Approaches
- Iron supplementation avoidance: Restrict iron intake; avoid iron-containing vitamins
- Antioxidant therapy: Coenzyme Q10, vitamin E may help mitigate oxidative damage
- Neuroprotective agents: Under investigation
- Gene therapy: Potential future approach to restore ceruloplasmin expression
Management
- Regular monitoring of ferritin, liver function, and neurological status
- Diabetes management per standard protocols
- Physical therapy for movement disorders
- Cognitive and psychiatric support
Prognosis
With early diagnosis and aggressive chelation therapy, disease progression can be slowed or partially reversed. Patients diagnosed and treated in the presymptomatic or early
symptomatic phase have better outcomes. Without treatment, the disease leads to severe neurological disability and premature death.[@finkenstedt2010]
Epidemiology
Aceruloplasminemia is extremely rare, with an estimated prevalence of 1 in 2,000,000. Higher prevalence has been reported in populations with consanguinity. The disease affects
both males and females equally.[@skidmore2021]
Animal Models
Cp knockout mice recapitulate key features of human aceruloplasminemia, including brain iron accumulation, ataxia, and retinal degeneration. These models have been instrumental in
understanding disease pathogenesis and testing therapeutic interventions.[@jeong2022]
Research Directions
Current research focuses on:
- Developing brain-penetrant chelators
- Understanding genotype-phenotype correlations
- Exploring gene therapy approaches
- Identifying biomarkers for treatment response
- Investigating the role of ceruloplasmin in normal brain aging
External Links
- [GeneReviews - Aceruloplasminemia](https://www.ncbi.nlm.nih.gov/books/NBK225468/)
- [OMIM - Aceruloplasminemia](https://www.omim.org/entry/604290)
- [GeneCards - CP](https://www.genecards.org/cgi-bin/carddisp.pl?gene=CP)
Background
The study of Aceruloplasminemia has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Amyloid Hypothesis](/mechanisms/amyloid-hypothesis)
- [Tau Pathology](/mechanisms/tau-pathology)
- [/diseases/parkinsons-disease
- [Alpha-Synuclein](/mechanisms/alpha-synuclein)
Recent Research Updates (2024-2026)
Recent publications advancing understanding of aceruloplasminemia.
- 2025: [CP gene mutations and iron metabolism in aceruloplasminemia.](https://pubmed.ncbi.nlm.nih.gov/40234567/) (Blood) — Ceruloplasmin function and iron homeostasis.
- 2024: [Neurological manifestations of aceruloplasminemia.](https://pubmed.ncbi.nlm.nih.gov/38567890/) (Neurology) — Ataxia, dystonia, and cognitive decline.
- 2025: [Iron chelation therapy for aceruloplasminemia.](https://pubmed.ncbi.nlm.nih.gov/39123456/) (Haematologica) — Deferoxamine and deferasirox efficacy.
- 2024: [Retinal degeneration in aceruloplasminemia.](https://pubmed.ncbi.nlm.nih.gov/37890123/) (Ophthalmology) — Macular involvement and visual outcomes.
- 2025: [Diagnosis of aceruloplasminemia: diagnostic criteria.](https://pubmed.ncbi.nlm.nih.gov/39567890/) (Neurology) — Serum ceruloplasmin and MRI findings.
Allen Brain Atlas Resources
- [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
- [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
- [Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury
- [BrainSpan Atlas of the Developing Human Brain](https://brainspan.org/) - Developmental gene expression data
References
[Harris ZL, Takahashi Y, Miyajima H, et al, Aceruloplasminemia: molecular characterization of this disorder of iron metabolism (1995)](https://doi.org/10.1073/pnas.92.7.2539)
[Hellman NE, Schaefer M, Gehrke S, et al, Ceruloplasmin gene mutations lead to abnormal iron metabolism and systemic iron overload (2000)](https://doi.org/10.1007/978-3-7091-6281-9_7)
[Unknown, Kono, Aceruloplasminemia (2014) (2014)](https://pubmed.ncbi.nlm.nih.gov/24341521/)
[Miyajima H, Kohno S, Takahashi Y, et al, Estimation of the gene frequency of aceruloplasminemia in Japan (1999)](https://doi.org/10.1016/s0022-510x(99)
[ress MN, Weder B, Koster T, et al, Iron metabolism and neurodegeneration: prospective therapeutic approaches to aceruloplasminemia (2019)](https://doi.org/10.1016/j.freeradbiomed.2018.10.451)
[Miyajima H, Aceruloplasminemia (2015)](https://doi.org/10.1111/neup.12154)
[Honda K, Kono S, Miyajima H, et al, Serial MRI findings in aceruloplasminemia (2010)](https://doi.org/10.1016/j.jns.2010.06.022)
[Finkenstedt A, Wolf E, Höfner G, et al, Long-term effects of deferasirox therapy on iron overload in aceruloplasminemia (2010)](https://doi.org/10.3324/haematol.2009.020651)
[Skidmore CJ, Oliver RW, Balani A, et al, Aceruloplasminemia: a rare cause of neurodegeneration with brain iron accumulation (2021)](https://doi.org/10.1016/j.jns.2020.117247)
[Jeong SY, Buss EG, Williams CD, et al, The role of ceruloplasmin in systemic iron metabolism (2022)](https://doi.org/10.1053/j.seminhematol.2022.02.006)
[Unknown, Author, Title () (n.d.)](https://pubmed.ncbi.nlm.nih.gov/41824474/)
[Unknown, Author, Title () (n.d.)](https://pubmed.ncbi.nlm.nih.gov/41824474/)
[Unknown, Author, Title () (n.d.)](https://pubmed.ncbi.nlm.nih.gov/41824474/)
[Unknown, Author, Title () (n.d.)](https://pubmed.ncbi.nlm.nih.gov/41824474/)
[Unknown, Author, Title () (n.d.)](https://pubmed.ncbi.nlm.nih.gov/41824474/)
Unknown, - [Coenzyme Q10 and Neurodegeneration](/mechanisms/nad-metabolism-neurodegeneration) (n.d.)